Qidong You
Professor
Director of Jiangsu Provincial Key Laboratory of Drug Molecular Design and Pharmacogenic Optimization
Email: youqd@163.com
Biography
After receiving the Doctor of Science degree in 1989, he went to China Pharmaceutical University to work as an associate professor, supervisor of postgraduate students, and deputy director of the Department of Medicinal Chemistry. In 1994, he was promoted to professor. In 1994, he went to the Department of Pharmacy, University of Strathclyde, UK for postdoctoral research, and was hired as doctoral supervisor after returning to China at the end of 1995. He also served as the director of the Department of Medicinal Chemistry of China Pharmaceutical University (1995-2006), the deputy Dean of the School of Pharmacy (1996-2006), and the Dean of the School of Pharmacy (2006-2015). He also served as the deputy director of the Academic Committee and the deputy director of the Academic Degree Committee. In 2012, he was approved by the Provincial Science and Technology Department to establish the Key Laboratory of Drug Molecular Design and Druggability Optimization in Jiangsu Province and served as the director.
Professor Qidong You is an advisory member of the 12th session of the National Pharmacopoeia Committee, an executive member of the 9th to 11th session of the National Pharmacopoeia Committee, and a Chairman of the Name and Terminology Committee. He is also a Council member of Chinese Pharmaceutical Society, a member of Academic Self-discipline and Academic Rights Protection Working Committee, Deputy Chairman of Pharmaceutical Chemistry Committee (2007, 2017), a member of Pharmaceutical Education Committee, Deputy Secretary-General, Executive Director of Jiangsu Pharmaceutical Society, Chairman of Provincial Pharmaceutical Chemistry Committee, Vice chairman and standing director ofNanjing Pharmaceutical Society,and chairman of pharmaceutical chemistry and pharmaceutical analysis committee. He is an expert in State Food and Drug Administration for national licensed pharmacist qualification certification, and also in National and Jiangsu Food and Drug Administration for new drug evaluation. He is a member of the Advisory Committee and Planning Committee of the Association of Pharmaceutical Schools of the International Federation of Pharmacy (FIP), and a member of the Council of Asian Pharmaceutical Schools.
Served as the editorial board member of SCI journal J Med Chem (IF= 8.039), Acta Pharmaceutica Sinica B (IF= 14.903) and Molecules (IF= 4.927) in Pharmaceutical Chemistry. He is on the editorial board of Chin J Pharm Sci and other international journals. He served as the chief editor of the Journal of Pharmacy and Clinical Research, the executive deputy editor of the Journal of China Pharmaceutical University, and the editorial board of 13 journals, including the Journal of Pharmaceutical Sciences and the Chinese Journal of Medicinal Chemistry.
Research Interests
He is mainly engaged in the research of medicinal chemistry and chemical biology. His research focuses on: molecular design and synthesis of new drugs, drug research on protein-protein interaction, etc..
Recent Publications
1. Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation. Jin Y, Fan J, Wang R, Wang X, Li N, You Q, Jiang Z. Journal of the American Chemical Society. 2023, 145(13):7218-7229. doi: 10.1021/jacs.2c12809（IF = 16.383）
2. Protein Phosphatase 5-Recruiting Chimeras for Accelerating Apoptosis-Signal-Regulated Kinase 1 Dephosphorylation with Antiproliferative Activity. Qiuyue Zhang, Xuexuan Wu, Hengheng Zhang, Qiuyu Wu, Min Fu, Liwen Hua, Xinyue Zhu, Yuqi Guo, Lianshan Zhang, Qidong You, Lei Wang. Journal of the American Chemical Society., 2023.145:1118-1128. https://doi.org/ 10.1021/jacs.2c10759. （IF = 16.383）
3. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang. Acta Pharmceutica Sinica B, 2022,12(7):2990-3005 https://doi.org/10.1016/j.apsb.2022.02.022（IF = 14.903）
4. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. Wang, L. *; Zhang, Q. Y.; You, Q. D.*, Medicinal Research Review. 2022. 42(1):156-182. https://doi.org/10.1002/med.21807.（IF = 13.3）
5. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. Wang, L. *; Zhang, Q. Y.; You, Q. D.*. Medicinal Research Review. 2022, 42 (1), 156-182.（IF = 13.3）
6. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Li Li, Nannan Chen, Dandan Xia, Shicheng Xu, Wei Dai, Yuanyuan Tong, Lei Wang, Zhengyu Jiang*, Qidong You*, Xiaoli Xu*. Cell Chemical Biology. 2021. 28：1446-1459. https://doi.org/10.1016/j.chembiol.2021.03.016 .（IF = 9.039）
7. The development of small molecules targeting methyltransferase-like 3. Li H, Zhang Q, Feng Q, You Q, Guo X. Drug Discov Today. 2023 Jan 31:103513. https://doi.org/10.1016/j.drudis.2023.103513.（IF = 8.369）
8. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications, T. Liu, Y.-F. Lv, J.-L. Zhao, Q.-D. You*, Jiang, Z.-Y.*, Free Radical Biology and Medicine., 168 (2021) 129-141.（IF = 8.101）
9. ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer. Jianai Ji, Sinan Ma, Yuxuan Zhu, Jinglong Zhao, Yuanyuan Tong, Qidong You, Zhengyu Jiang. Journal of Medicinal Chemistry. 2023, 66(9):6070-6081. https://doi:org/ 10.1021/acs.jmedchem.2c01909（IF = 8.039）
10. Development of Orally Bioavailable Amidobenzimidazole Analogues Targeting Stimulator of Interferon Gene (STING) Receptor. Chen NN, Zhang H, Zhu QS, Zeng T, Dai W, Zhou YL, Xin GF, Wu BD, Gong SJ, Jiang ZY, You QD, Xu XL. Journal of Medicinal Chemistry. 2023, 66(8):5584-5610. doi: 10.1021/acs.jmedchem.2c02046.（IF = 8.039）
11. Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance.Li H, Zhang SL, Jia YH, Li Q, Feng ZW, Zhang SD, Zheng W, Zhou YL, Li LL, Liu XC, Chen YQ, Peng H, You QD, Xu XL. Journal of Medicinal Chemistry. 2023, 66(4):2804-2831. doi: 10.1021/acs.jmedchem.2c01862. (IF = 8.039）
12. Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization. Liu W, Jiang J, Lin Y, You Q, Wang L. Journal of Medicinal Chemistry. 2022, 65(16): 10809–10847. doi: 10.1021/acs.jmedchem.2c00682.（IF = 8.039）
13. Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. Ma, Chang-you; Wu, Jian; Wang, Lei; Ji, Xiaojun; Wu, Yebin; Miao, Lei; Chen, Donghui; Zhang, Linlin; Wu, Youzhi; Feng, Haiwei; Tang, Ying; Zhou, Qiuhua; Pei, Junjie; Yang, Xule; Xu, Dan; You, Qidong; Xie, Yuan. Journal of Medicinal Chemistry, 2022, 65(12):8144-8168.（IF = 8.039）
14. Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. Hua L, Zhang Q, Zhu X, Wang R, You Q, Wang L. Journal of Medicinal Chemistry. 2022 65(12):8091-8112. doi: 10.1021/acs.jmedchem.2c00316.（IF = 8.039）
15. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. Zhu Q, Chen N, Tian X, Zhou Y, You Q, Xu X. Journal of Medicinal Chemistry. 2022, 65(12):8065-8090. doi: 10.1021/acs.jmedchem.2c00172.（IF = 8.039）
16. Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. Dai Z, An LY, Chen XY, Yang F, Zhao N, Li CC, Ren R, Li BY, Tao WY, Li P, Jiang C, Yan F, Jiang ZY, You QD, Di B, Xu LL. Journal of Medicinal Chemistry. 2022 65(6):5029-5043. doi: 10.1021/acs.jmedchem.1c02210.（IF = 8.039）
17. Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability. Zhu, P.-J.; Yu, Z.-Z.; Lv, Y.-F.; Zhao, J.-L.; Tong, Y.-Y.; Q.-D. You*, Jiang, Z.-Y.*, Journal of Medicinal Chemistry. 2021, 64 (15):11330-11353.（IF = 8.039）
18. Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. Xin Chen, Junjie Xu, Xianghan Wang, Guanlu Long, Qidong You* and Xiaoke Guo*. Journal of Medicinal Chemistry. 2021, 64(15), 10537-10556.（IF = 8.039）
19. Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer. Zhang, Q.; Fan, Z.; Zhang, L.; You, Q.*; Wang, L. *, Journal of Medicinal Chemistry. 2021. 64(13): 8916-8938.（IF = 8.039）
20. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5–Mixed Lineage Leukemia 1 Protein–Protein Interaction for the Treatment of MLL Fusion Leukemia, Weilin Chen, Xin Chen, Dongdong Li, Jianrui Zhou, Zhengyu Jiang*, Qidong You* and Xiaoke Guo*, Journal of Medicinal Chemistry. 2021, 64(12): 8221-8245.（IF = 8.039）
21. Novel Hydrogen Sulfide Hybrid Derivatives of Keap1-Nrf2 Protein-Protein Interaction Inhibitor Alleviate Inflammation and Oxidative Stress in Acute Experimental Colitis. Zhang X, Cui K, Wang X, Tong Y, Liu C, Zhu Y, You Q, Jiang Z, Guo X. Antioxidants. 2023，12(5):1062. doi: 10.3390/antiox12051062.（IF = 7.675）
22. Methods for the discovery and identification of small molecules targeting oxidative stress related protein-protein interactions: An update. Xuexuan Wu, Qiuyue Zhang, Yuqi Guo, Hengheng Zhang, Xiaoke Guo *, Qi-Dong You *, Lei Wang *. Antioxidants 2022, 11(4), 619; https://doi.org/10.3390/antiox11040619 （IF = 7.675）
23. Dual function of protein phosphatase 5 (PPP5C): An emerging therapeutic target for drug discovery. Zhang H, Zhang Q, Tu J, You Q, Wang L. European Journal of Medicinal Chemistry. 2023, 254:115350. doi: 10.1016/j.ejmech.2023.115350.（IF = 7.088）
24. A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation. Xuetao Chen, Liangying Zhang, Qichao Bao, Fanying Meng, Chihong Liu, Rujun Xu, Xinrui Ji, Qidong You, Zhengyu Jiang. European Journal of Medicinal Chemistry., 2023, 250:115198. https://doi.org/10.1016/j.ejmech.2023.115198（IF = 7.088）
25. Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors. Xinjian Tian, Feng Xu, Qiangsheng Zhu, Ziwen Feng, Wei Dai, Yeling Zhou, Qi-Dong You, Xiaoli Xu. European Journal of Medicinal Chemistry. 2022, 244:114791. https://doi.org/10.1016/j.ejmech.2022.114791（IF = 7.088）
26. A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. Jinying Gu, Qiuyu Wu. Qiuyue Zhang, Qidong You, Lei Wang. European Journal of Medicinal Chemistry. 2022, 243:114742https://doi.org/10.1016/j.ejmech.2022.114742（IF = 7.088）
27. Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6- dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis. Xuetao Chen, Fanying Meng, Jingtian Zhang, Zijian Zhang, Xuan Ye, Weikun Zhang, Yuanyuan Tong, Xinrui Ji, Rujun Xu, Xiao-Li Xu, Qi-DongYou, Zheng-Yu Jiang. European Journal of Medicinal Chemistry. 2022, 238:114423. https://doi.org/10.1016/j.ejmech.2022.114423 （IF = 7.088）
28. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity. Weilin Chen, Xin Chen, Dongdong Li, Xianghan Wang, Zhengyu Jiang*, Qidong You* and Xiaoke Guo*. European Journal of Medicinal Chemistry., 2021, 223, 113677（IF = 7.088）
29. Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects. Shicheng Xu, Anping Guo, Nan-nan Chen, Wei Dai, Huan-aoyu Yang, Wenqin Xie, Mengjie Wang, Qi-Dong You*, Xiao-Li Xu*. European Journal of Medicinal Chemistry. 2021. 223:113604. DOI: 10.1016/j.ejmech.2021.113604（IF = 7.088）
30. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core. Zhang, Q.; Wu, X.; Zhou, J.; Zhang, L.; Xu, X.; Zhang, L.; You, Q.*; Wang, L.*. European Journal of Medicinal Chemistry. 2021, 210:112959.（IF = 7.088）
31. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy, X. Li, J. Dou, Q.-D. You*, Jiang, Z.-Y.*, European Journal of Medicinal Chemistry., 220 (2021) 113539.（IF = 7.088）
32. An updated patent review of Nrf2 activators (2020-present). Ziquan Zhao, Ruitian Dong, Keni Cui, Qidong You & Zhengyu Jiang. Expert Opinion of Therapeutic Patents. 2023, 33(1):29-49. https://doi.org/10.1080/13543776.2023.2178299（IF = 6.714）
33. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Li Li, Nan-Nan Chen, Qi-Dong You* and Xiao-Li Xu*. Expert Opinion of Therapeutic Patents. 2021,31, 67-80.（IF = 6.714）
34. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020). Nan-Nan Chen, Han Zhang, Qi-Dong You* & Xiao-Li Xu*. Expert Opinion of Therapeutic Patents., 2021, 31:563-584.（IF = 6.714）
35. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors. Lingyue Zhao, Qian Yang, Yiqun Tang, Qidong You & Xiaoke Guo. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1):462-471. https://doi.org/10.1080/14756366.2021.2018683（IF = 5.756）
36. Recent applications of CBT-Cys click reaction in biological systems.Yuechao Zhu, Xian Zhang, QidongYou, Zhengyu Jiang. Bioorganic & Medicinal Chemistry. 2022, 68:116881. https://doi.org/10.1016/j.bmc.2022.116881（IF = 3.461）
37. An affinity prediction approach for the ligand of E3 ligase Cbl-b and an insight into substrate binding pattern, L.-B. Hu, X.-Q. Hu, Q. Zhang, Q.-D. You*, Jiang, Z.-Y.*, Bioorganic & Medicinal Chemistry, 2021, 38:116130.（IF = 3.461）
